Articles published by Aurion Biotech, Inc.

Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction

Today 7:00 EDT

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June

May 28, 2026

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026

May 06, 2026

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction

April 08, 2026

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D., to Chair Medical Advisory Board

March 11, 2026

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

March 18, 2025

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

February 10, 2025

From Aurion Biotech, Inc.

Via Business Wire

Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction

December 18, 2024

From Aurion Biotech, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Aurion Biotech, Inc.

Starting at /week.